Ubs Asset Management Americas Inc Esperion Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $58,089 - $290,445	39,787 Added 55.49%	111,482 $177,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $364,927 - $609,407	71,695 New	71,695 $446,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $121,055 - $179,150	6,240 Added 22.91%	33,476 $708,000
Q1 2021 May 14, 2021	BUY	$25.12 - $36.89 $106,383 - $156,229	4,235 Added 18.41%	27,236 $763,000
Q3 2020 Nov 13, 2020	SELL	$31.18 - $52.71 $6,454 - $10,910	-207 Reduced 0.89%	23,001 $854,000
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $117,276 - $200,314	3,904 Added 20.22%	23,208 $1.19 Million
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $51,203 - $137,785	-1,866 Reduced 8.81%	19,304 $608,000
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $3,115 - $5,264	88 Added 0.42%	21,170 $1.26 Million
Q3 2019 Nov 14, 2019	BUY	$34.47 - $47.53 $123,885 - $170,822	3,594 Added 20.55%	21,082 $772,000
Q2 2019 Aug 15, 2019	BUY	$40.1 - $52.33 $100,169 - $130,720	2,498 Added 16.66%	17,488 $0
Q1 2019 May 14, 2019	BUY	$40.11 - $53.57 $44,000 - $58,766	1,097 Added 7.9%	14,990 $0
Q4 2018 Feb 13, 2019	BUY	$36.99 - $59.11 $166,196 - $265,581	4,493 Added 47.8%	13,893 $639,000
Q3 2018 Nov 14, 2018	BUY	$40.74 - $51.41 $134,442 - $169,653	3,300 Added 54.1%	9,400 $0
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $2.2 Million - $4.64 Million	-60,674 Reduced 90.86%	6,100 $0
Q1 2018 May 14, 2018	BUY	$65.94 - $80.76 $97,591 - $119,524	1,480 Added 2.27%	66,774 $0
Q4 2017 Feb 09, 2018	BUY	$43.47 - $67.43 $1.1 Million - $1.71 Million	25,396 Added 63.65%	65,294 $0
Q3 2017 Nov 13, 2017	BUY	$43.8 - $52.77 $1.75 Million - $2.11 Million	39,898	39,898 $0

Others Institutions Holding ESPR

# of Institutions

210

Shares Held

129M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $120M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account